Answer
A TAKHZYRO (lanadelumab) 300 mg pre-filled syringe contains less than 1 mmol (23 mg) sodium and is considered essentially 'sodium-free'.
Sources for this answer
- TAKHZYRO 300 mg solution for injection in pre-filled syringeTakeda UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 8Document updated
Sources checked